Public Release: 

Drug resistance mutations also enhance growth in malaria parasite

Scientists identify and investigate key mutations in a parasite that causes severe malaria

PLOS

IMAGE

IMAGE: Gabryszewski used a gene editing technique based on "zinc-finger nucleases " to investigate the gene pfcrt that when mutated makes the malaria parasite Plasmodium falciparum resistant to chloroquine. These authors introduced... view more

Credit: Stanislaw Gabryszewski and David Fidock

Some mutations that enable drug resistance in the malaria-causing parasite Plasmodium falciparum may also help it grow, according to a new study published in PLOS Pathogens.

P. falciparum is a single-celled parasite that infects the human bloodstream and causes the most severe form of malaria. Some strains of P. falciparum have evolved resistance to antimalarial drugs, including the commonly used drug chloroquine. Often, chloroquine resistance mutations hinder P. falciparum's ability to infect the bloodstream and grow. However, in a previous study, Stanislaw Gabryszewski of Columbia University Medical Center, New York, and colleagues discovered that a uniquely mutated version of the P. falciparum gene known as pfcrt provides drug resistance while avoiding the detrimental impact of growth seen with more widely distributed mutated pfcrt variants.

In the new study, Gabryszewski's team investigated this version, or allele, of the pfcrt gene, which is called Cam734 and has been found in certain regions in Southeast Asia. Using DNA-modifying proteins called zinc-finger nucleases, they characterized the individual mutations unique to Cam734 in terms of their effects on drug resistance, metabolism, and growth rates in living parasites.

The researchers found that a mutation called A144F is required for the chloroquine resistance enabled by Cam734 and that this mutation also contributes to resistance to first-line drugs amodiaquine and quinine. Additional mutations were identified that contributed to resistance to chloroquine and impacted the potency of other antimalarials. When the scientists reversed these mutations in living parasites that had the Cam734 allele, growth slowed, indicating that these mutations also enhance infection.

Additional experiments identified specific effects of Cam734 mutations on several metabolic pathways in P. falciparum, including the digestion of human hemoglobin that parasites use to obtain amino acids for protein synthesis.

They also found evidence that Cam734 helps to maintain an electrochemical gradient that allows the protein encoded by the pfcrt gene to thwart the cellular effects of chloroquine.

These new findings significantly broaden scientists' understanding of Cam734, the second most common variant of the pfcrt gene in Southeast Asia. The findings identify multiple intracellular processes and multidrug resistance phenotypes impacted by changes in PfCRT and can help inform future malaria treatment efforts.

###

In your coverage please use this URL to provide access to the freely available article in PLOS Pathogens: http://dx.plos.org/10.1371/journal.ppat.1005976

Please contact plospathogens@plos.org if you would like more information.

Funding: Financial support for this work was provided by the National Institutes of Health: R01 AI50234 and AI109023 to DAF; F30 AI114070 to SJG; R01 AI110329 to TJE; and R01 AI506312 to PDR. IAL was supported by Alberta Innovates - Health Solutions (AIHS, Translational Health Chair), Canada Foundation for Innovation (CFI-JELF 34986), and the Natural Sciences and Engineering Research Council (NSERC, Discovery Grant 04547). ML was supported by the Burroughs Wellcome Fund (Investigators in Pathogenesis of Infectious Disease Award for Research), an NIH Director's New Innovators Award (1DP2OD001315), and the Center for Quantitative Biology (P50 GM071508). SJG gratefully acknowledges the Columbia University Medical Scientist Training Program for training support (T32 GM007367). JMC thanks the National Research Foundation South Africa for scholarship support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Gabryszewski SJ, Dhingra SK, Combrinck JM, Lewis IA, Callaghan PS, Hassett MR, et al. (2016) Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology. PLoS Pathog 12(11): e1005976. doi:10.1371/journal.ppat.1005976

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.